Education
About Us
Working with TipRanks
Follow Us
United Therapeutics Corp. (UTHR)
NASDAQ:UTHR
Total Valuation
United Therapeutics has a market cap or net worth of $23.35B. The enterprise value is $21.94B.
Market Cap$23.35B
Enterprise Value$21.94B
Share Statistics
United Therapeutics has 43,827,686 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding43,827,686
Owned by Insiders1.78%
Owned by Institutions8.20%
Financial Efficiency
United Therapeutics’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 15.88%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)15.88%
Return on Capital Employed (ROCE)0.20
Revenue Per Employee2.44M
Profits Per Employee1.02M
Employee Count1,305
Asset Turnover0.40
Inventory Turnover2.10
Valuation Ratios
The current PE Ratio of United Therapeutics is 16.2. United Therapeutics’s PEG ratio is 1.16.
PE Ratio16.2
PS Ratio6.78
PB Ratio3.04
Price to Fair Value3.04
Price to FCF20.74
Price to Operating Cash Flow15.21
PEG Ratio1.16
Income Statement
In the last 12 months, United Therapeutics had revenue of 3.18B and earned 1.33B in profits. Earnings per share was 30.13.
Revenue3.18B
Gross Profit2.80B
Operating Income1.49B
Pretax Income1.71B
Net Income1.33B
EBITDA1.82B
Earnings Per Share (EPS)30.13
Cash Flow
In the last 12 months, operating cash flow was 1.56B and capital expenditures -520.50M, giving a free cash flow of 1.04B billion.
Operating Cash Flow1.56B
Free Cash Flow1.04B
Free Cash Flow per Share23.75
Dividends & Yields
United Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.53
52-Week Price Change74.50%
50-Day Moving Average487.58
200-Day Moving Average410.63
Relative Strength Index (RSI)61.92
Average Volume (3m)448.46K
Important Dates
United Therapeutics upcoming earnings date is May 6, 2026, Before Open (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
United Therapeutics as a current ratio of 6.60, with Debt / Equity ratio of 0.00%
Current Ratio6.60
Quick Ratio6.28
Debt to Market Cap0.00
Net Debt to EBITDA-0.86
Interest Coverage Ratio76.54
Taxes
In the past 12 months, United Therapeutics has paid 379.20M in taxes.
Income Tax379.20M
Effective Tax Rate0.22
Enterprise Valuation
United Therapeutics EV to EBITDA ratio is 11.01, with an EV/FCF ratio of 19.24.
EV to Sales6.29
EV to EBITDA11.01
EV to Free Cash Flow19.24
EV to Operating Cash Flow12.83
Balance Sheet
United Therapeutics has $1.56B in cash and marketable securities with $0.00 in debt, giving a net cash position of $1.56B billion.
Cash & Marketable Securities$1.56B
Total Debt$0.00
Net Cash$1.56B
Net Cash Per Share$35.53
Tangible Book Value Per Share$157.56
Margins
Gross margin is 87.92%, with operating margin of 46.89%, and net profit margin of 41.94%.
Gross Margin87.92%
Operating Margin46.89%
Pretax Margin53.85%
Net Profit Margin41.94%
EBITDA Margin57.15%
EBIT Margin54.46%
Analyst Forecast
The average price target for United Therapeutics is $546.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$546.00
Price Target Upside2.47% Upside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast13.50%
EPS Growth Forecast17.16%